Seeking Novel Therapies for the Treatment of Skin Disorders

The newly established “External Innovation” Team at LEO Pharma, a Denmark-based global leader in medical dermatology, is actively scouting and sourcing new partnering or in-licensing opportunities within medical dermatology. Specifically, the team is interested in novel opportunities that modulate immuno-inflammatory targets/pathways with rationale for rare or common skin disorders, including but not limited to the treatment of eczema, epidermolysis bullosa, bullous pemphigoid, rosacea, hidradenitis suppurativa, alopecia areata, vitiligo and melasma.

Approaches of Interest:

• LEO Pharma is open to different modalities including small molecules, biologics, mRNA therapeutics or gene therapy approaches
• All potential routes of administration are of interest, with a preference for topical or oral delivery
• Drug repurposing/repositioning and therapeutics used to target mechanisms and pathways related to diseases of other tissues (e.g. asthma), which have potential to be applied to treatment of skin disorders are of interest 

Out of Scope:

• Skin cancer / melanoma and infectious skin disorders
• Aesthetic or cosmetic products and opportunities related to scarring and wound healing
• Stem cells / stem cell therapy
• Opportunities related to drug screening approaches 

Developmental Stages of Interest:

• Opportunities from basic research phase to Phase III stage are within scope
• For opportunities in preclinical stages, evidence of efficacy (in vitro or in vivo), is preferred 

Submission Information

Submission of one-page, 200–300-word briefs is encouraged, along with any optional supplementary information e.g. relevant publications. In submitting to this campaign, you confirm that your submission contains only non-confidential information. To submit, please visit our website.

Opportunity for Collaboration

Our client is open to a range of collaboration opportunities, with the most appropriate outcome being decided on a case-by-case basis. Example outcomes include licensing assets, project/PhD funding, and research collaborations.